Federal antitrust regulators are eyeing big drugmaker Mylan’s EpiPen business, the company said Monday.
Mylan, in a statement, said the Federal Trade Commission asked it “months ago” for information about its anti-allergy EpiPen “as part of a preliminary investigation.”
The disclosure comes nearly five months after two United States senators asked the FTC to investigate whether Mylan violated antitrust laws to protect the auto-injector EpiPen from competition.
Those lawmakers’ interest in EpiPen in turn was sparked by consumer outrage over Mylan having raised the price of the device more than 500 percent in recent years, to more than $600 per two-pack.
“Mylan received an information request from the FTC months ago as part of a preliminary investigation,” said Mylan spokeswoman Nina Devlin on Monday.
“Any suggestion that Mylan took any inappropriate or unlawful actions to prevent generic competition is without merit,” Devlin said.
“We note that the epinephrine auto-injector market is and always has been competitive, with multiple products competing on the market since we acquired EpiPen Auto-Injector.”
“Further, Teva has had patent licenses to launch their proposed generic alternative to EpiPen Auto-Injector since June 2015, pending FDA approval, years prior to patent expiry,” Devlin said.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Veteran Lawyers Launch Boutique Antitrust Firm in NY and DC
Oct 6, 2024 by
CPI
EU’s Top Court Upholds Antitrust Veto on Thyssenkrupp-Tata Steel Deal
Oct 6, 2024 by
CPI
Brazil’s Court Delays X’s Return Over Fine Payment Dispute
Oct 6, 2024 by
CPI
Tencent and Guillemot Family Consider Potential Buyout of Ubisoft
Oct 6, 2024 by
CPI
Second Price-Fixing Case Against Hotel-Casinos Dismissed by Federal Judge
Oct 6, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh